Domestic purchasing channels and guide for Bezutivan
Belzutifan is a new type of oral hypoxia-inducible factor-2α (HIF-2α) inhibitor. It is mainly used to treat tumor diseases related to von Hippel-Lindau disease (VHL), including renal cell carcinoma (RCC) and central nervous system hemangioblastoma. In clinical applications, bestifan can effectively reduce the growth and metastasis of tumor cells by inhibiting the activity ofHIF-2α, showing good efficacy.
In China, bezotivan has been marketed, but due to its short time on the market, its price and medical insurance coverage are still unclear. On the market, we can mainly see the Hong Kong version of the original research drug, the drug specification is 40mg*90 tablets, and the price is usually around 100,000 yuan, which is relatively high. This puts many patients under greater financial pressure, especially when long-term medication is required.

In addition, when patients are looking for purchasing channels, they can consider some overseas drug purchasing platforms, which provide the Lao version of generic drugs at relatively cheap prices. Each box sells for more than 5,000 yuan, and the drug ingredients are basically the same as the original drugs. However, since cross-border drug purchases are involved, attention needs to be paid to the legality and quality assurance of the drugs.
Before using bestivan, patients should follow their doctor's advice and undergo necessary examinations to ensure suitability of the drug. At the same time, treatment effects and possible side effects need to be monitored regularly so that treatment plans can be adjusted in a timely manner. Because individual responses to medications vary, treatment planning is critical.
In short, as a new anti-cancer drug, bestivan shows promise in the treatment of tumors related to VHL disease. However, due to its high price and market supply problems, patients need to carefully choose the purchasing channel when obtaining the drug and use it under the guidance of professional medical personnel.
Reference materials:https://www.welireg.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)